Psilera
- Company typePrivate
- Founded2019
- HeadquartersTampa, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Psilera does
Psilera is a Tampa, Florida-based, scientist-led biopharmaceutical company founded in 2019 that engineers next-generation neuroplastogen therapies for neuropsychiatric and neurodegenerative disorders. Its lead clinical asset, PSIL-006, is a non-hallucinogenic psilocybin derivative designed for take-home use and insurability, targeting behavioral variant frontotemporal dementia (bvFTD) as the lead indication and Alcohol Use Disorder (AUD) as a secondary program. The company's underlying platform includes a proprietary compound library covering over 1 million novel compounds across six serotonergic families, a novel 4-Br-DMT synthetic chemistry method (published in ACS Omega), and a computational chemistry platform branded "Psilera Third Eye." IP portfolio comprises 13 patents filed with 2 issued from USPTO.
Psilera has assembled a research and development ecosystem spanning NIDA's Designer Drug Research Unit, the University of South Florida Morsani College of Medicine, Hesperos (organ-on-a-chip), and the University of Wisconsin-Madison. The company is pre-revenue and not yet commercial; its business model is structured around pharmaceutical licensing and royalties, government and non-dilutive grant funding, and eventual drug commercialization. A licensing agreement with atai Life Sciences (February 2025) for the DMT patent portfolio provides eligibility for development milestones and royalties on commercial product sales. Cumulative capital raised is approximately $11.3 million across multiple seed rounds, a Series Seed extension, and NIH/Florida High Tech Corridor grants.
The company's go-to-market is sales-led and oriented toward partnership and funding engagement: it presents at industry and investor conferences (Oppenheimer CNS Summit, BIO International, Neuropsychiatric Drug Development Summit) and pursues IND-enabling work targeting first-in-human trials in 2027. Distribution post-approval is anticipated through standard pharmaceutical channels, with PSIL-006 designed for prescription and pharmacy fulfillment. Customer end-markets are patients with bvFTD, AUD, and other treatment-resistant neurological conditions; intermediate "customers" are licensing partners (atai), research collaborators (NIDA, USF, Hesperos), and grant providers (NIH, Florida High Tech Corridor).
Psilera firmographics
Firmographics- Name
- Psilera
- Legal name
- Psilera Inc.
- Website
- https://psilera.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Psilera industry classification
Industry- Product category
- Neurological Therapeutics
- NAICS
- Scientific Research and Development Services (5417)
- akta.pro primary industry
- Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)
Keywords
Where Psilera is headquartered
LocationHeadquarters
- HQ city
- Tampa
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Psilera business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Licensing and Royalties: Revenue from licensing proprietary compounds and patent portfolios to larger pharmaceutical companies, including milestone payments and royalties on commercial product sales. Psilera has a licensing agreement with atai Life Sciences for DMT patent portfolio and is eligible for payments related to certain future development milestones as well as royalties on commercial product sales.
- Drug Development and Commercialization: Revenue from developing and commercializing proprietary neuroplastogen therapeutics. Lead compound PSIL-006 advancing toward first-in-human trials targeting frontotemporal dementia and potentially alcohol use disorder.
- Government and Non-Dilutive Funding: Grants from NIH ($2 million for AUD research) and Florida High Tech Corridor ($130,000+) for specific research programs, providing non-dilutive capital for preclinical and clinical development.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | No consumer product pricing available - company is in discovery/clinical stage |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
Psilera product offering
Product offeringCore offering
Psilera is a clinical-stage biopharmaceutical company that discovers and develops proprietary neuroplastogen small molecule therapeutics for neuropsychiatric and neurodegenerative disorders. Its lead asset, PSIL-006, is a non-hallucinogenic psilocybin derivative advancing toward first-in-human trials in 2027 for behavioral variant frontotemporal dementia and alcohol use disorder. The company leverages a proprietary synthetic chemistry platform and a compound library of over 1 million novel molecules across six serotonergic families.
Product overview
Psilera is a scientist-led biopharmaceutical company pioneering next-generation precision neuroscience through engineering novel neuroplastogen therapies. The company operates with a multi-product portfolio centered on its lead clinical asset PSIL-006, a first-in-class non-hallucinogenic psilocybin derivative advancing toward first-in-human trials in 2027 for behavioral variant frontotemporal dementia. Supporting the core product is an in-house research pipeline featuring six serotonergic compound families with over 1 million novel compounds in their proprietary library, and a novel synthetic chemistry platform enabling expansion into new chemical space beyond the lead compound. The company has 13 patents filed (2 issued from USPTO covering over 1 million novel compounds) and maintains collaborated programs with AtaiBeckley covering DMT patent portfolio.
Differentiator
Problem solved
Functional benefit
Products and services
- PSIL-006 Lead clinical asset and next-generation psilocybin derivative with non-hallucinogenic profile designed for take-home use and insurability. Advancing toward first-in-human clinical trials in 2027 for behavioral variant frontotemporal dementia (bvFTD) and Alcohol Use Disorder (AUD).
Quantifiable outcome
- No treatment-limiting side effects (hallucinations) in preclinical testing
- +3 more outcomes
Companies that use Psilera
Customer profileSegments2 records
Ideal customer profiles3 records
Psilera technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Psilera partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- atai Life Sciences (AtaiBeckley)corePsilera entered a strategic licensing agreement with atai Life Sciences for their DMT patent portfolio. The collaboration covers all granted and pending patents related to DMT and other related psychedelics. Psilera is eligible for payments related to certain future development milestones as well as certain royalties on commercial product sales.
- National Institute on Drug Abuse (NIDA)coreCollaboration with NIDA's Designer Drug Research Unit on Psilera's novel synthetic platform research published in ACS Omega. The partnership demonstrates ability to develop compounds with new customizable functional groups for neuroplastogen discovery.
- University of South FloridacoreLong-standing collaboration with USF's Morsani College of Medicine since 2019. Research collaborations include preclinical studies on DMT derivatives, small mammal behavior testing with Dr. Dani Gulick, and computational chemistry with Dr. Steven Austin. USF Research Foundation has also invested in Psilera's FTD research.
- HesperoscoreCollaboration since 2025 with drug development leader Hesperos, developers of organ-on-a-chip technology. Hesperos is being used to study disease mechanisms and drug efficacy in preclinical stages of PSIL-006 for frontotemporal dementia.
- University of Wisconsin-MadisonminorResearch collaboration with Cody Wenthur, PharmD & PhD, Assistant Professor and Director of Psychoactive Pharmaceutical Investigation, since 2021. Collaboration focuses on developing chemical and biological tools to uncover shared molecular deficits in stress management and reward function. Also includes Dr. Christopher Nicholas for clinical development advisory.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Psilera competitors and assessment
Company assessmentDirect peers
- atai Life Sciences (AtaiBeckley): Public clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic therapies for mental health disorders. Already a direct partner via DMT patent licensing and a primary peer as both pursue neuroplastogen and DMT-based therapeutics for psychiatric indications.
- Delix Therapeutics: Clinical-stage neuroscience company developing non-hallucinogenic neuroplastogens for depression, PTSD, and other CNS conditions. Extremely comparable to Psilera in mechanism, therapeutic area, and non-hallucinogenic differentiation strategy.
- Compass Pathways: Public clinical-stage company pioneering psilocybin therapy for treatment-resistant depression. Competes in the same psychedelic medicine space targeting neuropsychiatric indications with a similarly neuroplasticity-focused scientific thesis.
- MindMed: Public clinical-stage company developing psychedelic-inspired medicines including LSD and MDMA analogs for anxiety, depression, and addiction. Targets similar neuropsychiatric indications and pursues both hallucinogenic and non-hallucinogenic programs.
- Gilgamesh Pharmaceuticals: Clinical-stage biopharmaceutical company developing psychedelic-inspired neuroplastogens and breakthrough mental health treatments. Highly comparable in platform approach, target indications, and non-hallucinogenic differentiation.
- Cybin: Public clinical-stage company developing psilocybin-based therapeutics for depression and addiction. Operates in the same psychedelic therapeutics space targeting overlapping indications including alcohol use disorder.
- GH Research: Public clinical-stage biopharmaceutical company developing mebufotenin (5-MeO-DMT) therapies for treatment-resistant depression. Directly comparable in psychedelic tryptamine chemistry and CNS therapeutic focus.
- Tactogen: Public-benefit biotech developing non-hallucinogenic MDMA-inspired medicines (entactogens) for PTSD, depression, and other CNS conditions. Closely comparable to Psilera in pursuing safer, scalable psychedelic-inspired neuroplastogens.
- Small Pharma: Clinical-stage biotech developing DMT-based therapies for depression. Direct comparable on tryptamine chemistry, serotonin receptor targeting, and psychedelic-inspired therapeutic platform approach.
Emerging players
- Lobe Sciences: Emerging biotech developing psychedelic-inspired therapeutics for neurological and inflammatory conditions. Less clinically advanced but pursues overlapping neuroplastogen mechanisms of action with similar CNS indication focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Psilera social profiles
Digital presencePsilera financial estimates
Financial estimateRevenue estimate
Valuation estimate
Psilera leadership team
Management profileNumber of profiles
Profiles7 records
Psilera funding detail
Funding detailFunding overview
Funding rounds5 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Psilera M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Psilera
What does Psilera do?
Psilera is a clinical-stage biopharmaceutical company that discovers and develops proprietary neuroplastogen small molecule therapeutics for neuropsychiatric and neurodegenerative disorders. Its lead asset, PSIL-006, is a non-hallucinogenic psilocybin derivative advancing toward first-in-human trials in 2027 for behavioral variant frontotemporal dementia and alcohol use disorder. The company leverages a proprietary synthetic chemistry platform and a compound library of over 1 million novel molecules across six serotonergic families.
Is Psilera a public or private company?
Psilera is a private company. It is classified as venture growth investor backed and is currently operating.
When was Psilera founded?
Psilera was founded in 2019. It employs 1 to 10 people.
Where is Psilera based?
Psilera is headquartered in Tampa, United States, in the North America region.
How does Psilera make money?
Three revenue lines are on record. Pharmaceutical Licensing and Royalties are the primary driver. The others are drug Development and Commercialization and government and Non-Dilutive Funding.
Who are Psilera's main competitors?
Direct peers on record are atai Life Sciences (AtaiBeckley), Delix Therapeutics, Compass Pathways, MindMed, Gilgamesh Pharmaceuticals, Cybin, GH Research, Tactogen and Small Pharma. Lobe Sciences is listed as an emerging player.
Does Psilera have an API?
No public API is recorded for Psilera.
What industry is Psilera in?
Psilera's product category is Neurological Therapeutics. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 5417.